S&P 500
5,939.30
-0.5%
-$31.51
DJI
42,319.74
-0.3%
-$108.00
NASDAQ
19,298.45
-0.8%
-$162.04
Bitcoin
101,699.00
-3.1%
-3,238.68
AAPL
$200.39
-1.2%
-$2.43
AMZN
$207.76
+0.3%
+$0.53
GOOG
$169.74
+0.2%
+$0.35
META
$683.71
-0.6%
-$4.24
MSFT
$467.07
+0.7%
+$3.20
NVDA
$139.88
-1.4%
-$2.04
TSLA
$285.20
-14.1%
-$46.85
Medicenna Therapeutics (NASDAQ: MDNA)
Some price data may be temporarily unavailable.
Medicenna Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Medicenna Therapeutics Company Info
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.